Enoxaparin improves COVID-19 by reducing Neutrophils Extracellular Traps (NETs) production

COVID-19 causes consequences such as imbalance of the immune system and thrombotic events. During the infection process, NETs in excess induce a pro-inflammatory response and disseminated intravascular coagulation. We evaluated the role of enoxaparin as a potential inhibitor of NETs. K18-hACE2 anima...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Vol. 257; p. 109836
Main Authors: Córneo, Emily S., Veras, Flavio Protasio, Gomes, Giovanni F., Schneider, Ayda H., Manuella, Bruna, Almeida, Cicero J.L.R., Silva, Camila M., Martins, Ronaldo B., Batah, Sabrina S., Simon, Carla S., Prestes, Gabriele da S., Alves-Filho, José Carlos, Arruda, Eurico, Louzada-Junior, Paulo, de Oliveira, Renê D.R., Fabro, Alexandre T., Cunha, Thiago M., Cunha, Fernando Queiroz, Dal-Pizzol, Felipe
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.12.2023
Subjects:
Animals
COVID-19
Enoxaparin
Enoxaparin - pharmacology
Extracellular Traps
Humans
Inflammatory markers
Lung injury
NETs
Neutrophils
SARS-CoV-2
PBS
Enoxaparin
Inflammatory markers
PFA
MPO
H3Cit
COVID-19
SOFA
SARS-CoV-2
NETs
Enox
NE
Lung injury
PAD-4
ISSN:1521-6616, 1521-7035, 1521-7035
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:COVID-19 causes consequences such as imbalance of the immune system and thrombotic events. During the infection process, NETs in excess induce a pro-inflammatory response and disseminated intravascular coagulation. We evaluated the role of enoxaparin as a potential inhibitor of NETs. K18-hACE2 animals infected with the SARS-CoV-2 virus and a group of 23 individuals admitted to the hospital with COVID-19 treated with enoxaparin or without treatment and controls without the disease were included. Enoxaparin decreased the levels of NETs, reduced the signs of the disease and mitigated lung damage in the animals infected with SARS-CoV-2. These effects were partially associated with prevention of SARS-CoV-2 entry and NETs synthesis. Clinical data revealed that treatment with enoxaparin decreased the levels of inflammatory markers, the levels of NETs in isolated neutrophils and the organ dysfunction. This study provides evidence for the beneficial effects of enoxaparin in COVID-19 in addition to its anticoagulant role.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1521-6616
1521-7035
1521-7035
DOI:10.1016/j.clim.2023.109836